SHANGHAI, Dec. 7, 2010 /PRNewswire-Asia-FirstCall/ --
China-Biotics, Inc. ("China-Biotics" or "the Company"), (Nasdaq:
CHBT) the leading developer, manufacturer and distributor of
probiotics products in China,
today announced that a delegation from the Company's research and
development department presented at the National Probiotics
Research and Development, New Application and Equipment seminar in
Hangzhou, China on November 21st.
The seminar was organized and hosted by the National High-Tech
Industrialization Association. More than 180 research and
development professionals from global industry leaders and other
probiotics companies participated in the event.
The Company's R&D specialists presented on bifidobacterium
infantis, focusing on the fermentation techniques, quality
assurance on product stability, and the application of
bifidobacterium infantis in health food products.
Mr. Jinan Song, Chairman and CEO
of China-Biotics, commented, "Research and development and the
application of probiotics is accelerating in China as consumers continue to grasp the
beneficial effects of probiotics. Meanwhile, the Chinese government
is also poised to implement stricter enforcement to reduce the use
of antibiotics use in animal feed. As a result, the probiotics
industry is experiencing linear growth with rising popularity among
consumers and favorable policy supports. Advancement in production
techniques and the gradual standardization of industry practices
have laid the foundation for more dairy and animal producers to
embrace probiotics."
About China-Biotics
China-Biotics, Inc. ("China-Biotics" or "the Company"), a
leading manufacturer of biotechnology products and supplements,
engages in the research, development, marketing and distribution of
probiotics dietary supplements in China. Through its wholly owned subsidiaries,
Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering
(Shanghai) Co. Ltd., the Company
develops and produces its proprietary product portfolio. Currently,
the retail products are sold OTC mainly through large distributors
to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. The Company also sells bulk
products to institutional customers such as dairy and animal feed
producers, as well as pharmaceutical companies. In February 2010, China-Biotics began its commercial
production in China's largest
probiotics production facility to meet growing demand in
China. For more information,
please visit http://www.chn-biotics.com.
Safe Harbor Statement
The information in this release contains forward-looking
statements which involve risks and uncertainties, including
statements regarding the Company's capital needs, business strategy
and expectations. Any statements contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements, which may be identified by terminology such as "may,"
"should," "will," "expect," "plan," "intend," "anticipate,"
"believe," "estimate," "predict," "potential," "forecast,"
"project," or "continue," the negative of such terms or other
comparable terminology. Readers should not rely on forward-looking
statements as predictions of future events or results. Any or all
of the Company's forward-looking statements may turn out to be
wrong. They can be affected by inaccurate assumptions, risks and
uncertainties and other factors which could cause actual events or
results to be materially different from those expressed or implied
in the forward-looking statements. In evaluating these statements,
readers should consider various factors, including the risks
described in "Item 1A. Risk Factors" beginning on page 17 and
elsewhere in the Company's 2010 Annual Report on Form 10-K. These
factors may cause the Company's actual results to differ materially
from any forward-looking statement. In addition, new factors emerge
from time to time and it is not possible for the Company to predict
all factors that may cause actual results to differ materially from
those contained in any forward- looking statements. The Company
disclaims any obligation to publicly update any forward-looking
statements to reflect events or circumstances after the date of
this document, except as required by applicable law.
Contact:
|
|
|
|
Travis Cai
|
|
Chief Financial Officer
|
|
China-Biotics, Inc.
|
|
traviscai@chn-biotics.com
|
|
|
|
Shiwei Yin/Dixon Chen
|
|
Grayling
|
|
646-284-9474
|
|
shiwei.yin@grayling.com
|
|
dixon.chen@grayling.com
|
|
|
SOURCE China-Biotics, Inc.